Aldeyra Therapeutics, Inc. ALDX
Set alert
At close
Pre-market · Nov 2, 8:28 AM ET
- YTD
- -89.18%
- 1 year
- -88.86%
- Open
- 0.67
- Prev close
- 0.6591
- Mkt cap
- 33.80M
- Vol
- 896.63K
- Avg vol
- 1.16M
- EPS
- -0.38
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 0.5502
- High
- 0.68
- Forward P/E
- -7.80
- Beta
- 1.43
- Short ratio
- 6.19
- Inst. own
- 62.19%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Oct 3, 2024
- 50-d avg
- 5.12
- 200-d avg
- 4.48
- 1y target
- 10.00
News
2 weeks ago benzinga.com
12 Health Care Stocks Moving In Friday's After-Market Session
Gainers Silexion Therapeutics (NASDAQ:SLXN) shares moved upwards by 11.0% to $0.17 during Friday's after-market session. The company's market cap stands at $2.4 million. Lexaria Bioscience…
3 weeks ago benzinga.com
12 Health Care Stocks Moving In Tuesday's After-Market Session
Gainers China SXT Pharmaceuticals (NASDAQ:SXTC) shares moved upwards by 64.0% to $2.05 during Tuesday's after-market session. The market value of their outstanding shares is at $1.1 million. Neogen…
-
3 weeks ago benzinga.com
12 Health Care Stocks Moving In Monday's Intraday Session
Gainers HeartBeam (NASDAQ:BEAT) stock moved upwards by 70.5% to $0.74 during Monday's regular session. The market value of their outstanding shares is at $24.4 million. PDS Biotechnology…
-
1 month ago benzinga.com
HC Wainwright & Co. Reiterates Neutral on Aldeyra Therapeutics, Maintains $2 Price Target
HC Wainwright & Co. analyst Matthew Caufield reiterates Aldeyra Therapeutics (NASDAQ:ALDX) with a Neutral and maintains $2 price target.
1 month ago benzinga.com
Aldeyra Fights Back Against FDA Rejection, Dispute Plan Triggers Rally
Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) shares are trading higher on Tuesday as investors react to the company's intent to submit a formal dispute resolution request tied to its reproxalap program.
1 month ago benzinga.com
Aldeyra Fights Back Against FDA Rejection, Dispute Plan Triggers Rally
Aldeyra Therapeutics stock surges as the company files an FDA dispute resolution for its dry eye drug reproxalap following a rejection.
1 month ago seekingalpha.com
Aldeyra Therapeutics, Inc. (ALDX) Discusses FDRR and FDA Review Process for Reproxalap in Dry Eye Disease Transcript
Aldeyra Therapeutics, Inc. (ALDX) Discusses FDRR and FDA Review Process for Reproxalap in Dry Eye Disease Transcript
-
1 month ago benzinga.com
BTIG Reiterates Buy on Aldeyra Therapeutics, Maintains $9 Price Target
BTIG analyst Thomas Shrader reiterates Aldeyra Therapeutics (NASDAQ:ALDX) with a Buy and maintains $9 price target.
1 month ago marketbeat.com
Aldeyra to Appeal FDA Rejection of Reproxalap for Dry Eye Disease
Aldeyra Therapeutics NASDAQ: ALDX said it plans to submit a formal dispute resolution request, or FDRR, to the FDA's Office of New Drugs seeking review of the agency's latest complete response letter…
1 month ago businesswire.com
Aldeyra Therapeutics Announces Intent to Submit Formal Dispute Resolution Request for Reproxalap to Treat Dry Eye Disease
CONCORD, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat…
1 month ago businesswire.com
Aldeyra Therapeutics to Host Regulatory Update Webcast
CONCORD, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat…
3 months ago benzinga.com
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Gainers Gossamer Bio (NASDAQ:GOSS) shares moved upwards by 47.2% to $0.29 during Tuesday's pre-market session. The company's market cap stands at $97.4 million. Prelude Therapeutics (NASDAQ:PRLD)…
3 months ago globenewswire.com
Levicept Appoints Darlene Deptula-Hicks as CFO
Highly Experienced US-Based Public Markets Leader Strengthens Team as Company Drives Late Stage Development of LEVI-04 for Osteoarthritis Highly Experienced US-Based Public Markets Leader Strengthens…
4 months ago gurufocus.com
Aldeyra Therapeutics Appoints Darlene Deptula-Hicks to Board of Directors
Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immun
4 months ago businesswire.com
Aldeyra Therapeutics Appoints Darlene Deptula-Hicks to Board of Directors
LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat…
-
4 months ago benzinga.com
12 Health Care Stocks Moving In Friday's After-Market Session
12 Health Care Stocks Moving In Friday's After-Market Session
5 months ago marketbeat.com
Aldeyra Therapeutics Eyes FDA Feedback as Dry Eye Drug Faces Make-or-Break Moment
Aldeyra Therapeutics NASDAQ: ALDX Chief Executive Todd Brady said the company expects near-term feedback from the U.S. Food and Drug Administration on its dry eye disease candidate reproxalap,…
5 months ago businesswire.com
Aldeyra Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference
LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat…
5 months ago newsfilecorp.com
Bronstein, Gewirtz & Grossman LLC Urges Aldeyra Therapeutics, Inc. Investors to Act: Class Action Filed Alleging Investor Harm
New York, New York--(Newsfile Corp. - May 29, 2026) - Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed…
5 months ago gurufocus.com
ALDX Investors Have Opportunity to Lead Aldeyra Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
[url="]The Schall Law Firm[/url], a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Aldeyra Therapeutics, Inc.
5 months ago gurufocus.com
ALDX FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Aldeyra Therapeutics (ALDX) Investors of Securities Class Action Deadline on May 29, 2026
[url="]Faruqi and Faruqi, LLP[/url], a leading national securities law firm, is investigating potential claims against Aldeyra Therapeutics, Inc. (âAldeyraâ
5 months ago businesswire.com
ALDX Investors Have Opportunity to Lead Aldeyra Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
LOS ANGELES--(BUSINESS WIRE)---- $ALDX--ALDX Investors Have Opportunity to Lead Aldeyra Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm.
5 months ago newsfilecorp.com
ALDX FINAL DEADLINE: ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages Aldeyra Therapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important May 29 Deadline in Securities Class Action First Filed by the Firm - ALDX
New York, New York--(Newsfile Corp. - May 29, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) between…
5 months ago businesswire.com
ALDX FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Aldeyra Therapeutics (ALDX) Investors of Securities Class Action Deadline on May 29, 2026
NEW YORK--(BUSINESS WIRE)---- $ALDX #ALDX--Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Aldeyra Therapeutics, Inc. (“Aldeyra” or the…
5 months ago globenewswire.com
ALDX UPCOMING DEADLINE : The Gross Law Firm Alerts Aldeyra Therapeutics, Inc. Stockholders of Securities Class Action - Contact the Firm
NEW YORK, May 29, 2026 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Aldeyra Therapeutics, Inc. (NASDAQ: ALDX). Shareholders who purchased shares of ALDX…
5 months ago newsfilecorp.com
ALDX SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Reminds Aldeyra Therapeutics (ALDX) Investors of Securities Class Action Deadline on May 29, 2026
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Aldeyra To Contact Him Directly To Discuss Their Options If you purchased or…
5 months ago prnewswire.com
ALDX Deadline Tomorrow: ALDX Investors with Losses in Excess of $100K Have Opportunity to Lead Aldeyra Therapeutics, Inc. Securities Fraud Lawsuit Filed by The Rosen Law Firm
NEW YORK, May 28, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) between November 3, 2023…
5 months ago globenewswire.com
ALDEYRA DEADLINE: ROSEN, THE FIRST FILING FIRM, Encourages Aldeyra Therapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important May 29 Deadline in Securities Class Action First Filed by the Firm - ALDX
NEW YORK, May 28, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) between November 3,…
-
7 months ago benzinga.com
12 Health Care Stocks Moving In Thursday's Intraday Session
12 Health Care Stocks Moving In Thursday's Intraday Session
7 months ago benzinga.com
What's Going On With Aldeyra Therapeutics Stock On Thursday?
Aldeyra stock plunges after FDA rejects its dry eye drug reproxalap, raising concerns over efficacy and future growth prospects.
7 months ago benzinga.com
This Trade Desk Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday
Analysts downgraded CF, ALDX, TTD, TME and DUOL. Check their ratings and price targets. Interested in TTD? See what analysts say.
-
7 months ago benzinga.com
HC Wainwright & Co. Downgrades Aldeyra Therapeutics to Neutral, Lowers Price Target to $2
HC Wainwright & Co. analyst Matthew Caufield downgrades Aldeyra Therapeutics (NASDAQ:ALDX) from Buy to Neutral and lowers the price target from $10 to $2.
-
7 months ago benzinga.com
12 Health Care Stocks Moving In Tuesday's Intraday Session
12 Health Care Stocks Moving In Tuesday's Intraday Session
7 months ago benzinga.com
FDA Rejects Aldeyra's Dry Eye Drug For Third Time, Stock Crashes 68%
Aldeyra stock crashes 68% after the FDA rejects its dry eye drug, reproxalap, for the third time. Get the full regulatory update here.
7 months ago benzinga.com
Crude Oil Gains Around 2%; Elbit Systems Shares Jump On Upbeat Earnings
US stocks rose, with Dow Jones up 0.39% & NASDAQ up 0.59%. Energy shares jumped 1.7%, while industrials fell 0.1%. Elbit Systems shares up 10%.
7 months ago benzinga.com
Nasdaq Surges Over 100 Points; Academy Sports And Outdoors Posts Downbeat Earnings
US stocks started higher this morning, with NASDAQ up over 100 points. Energy shares rose by 1.3%, while Aldeyra and Meiwu Tech saw sharp declines.
-
7 months ago benzinga.com
Aldeyra Therapeutics Receives CRL From FDA For NDA Of Reproxalap, Investigational Drug Candidate, For Treatment Of Dry Eye Disease
Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated diseases, today announced…
-
7 months ago benzinga.com
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
10 months ago benzinga.com
12 Health Care Stocks Moving In Tuesday's Intraday Session
12 Health Care Stocks Moving In Tuesday's Intraday Session
10 months ago benzinga.com
FDA Extends Review Timeline For Aldeyra's Dry Eye Disease Drug
FDA extends Aldeyra's reproxalap PDUFA date to March 2026 after a major NDA amendment tied to new clinical study report data.
-
10 months ago benzinga.com
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
10 months ago benzinga.com
Why B. Riley Financial Shares Are Trading Higher By Around 25%; Here Are 20 Stocks Moving Premarket
Why B. Riley Financial Shares Are Trading Higher By Around 25%; Here Are 20 Stocks Moving Premarket
-
11 months ago benzinga.com
Aldeyra Therapeutics Expands RASP Platform To Include Programs In Central Nervous System Diseases Associated With Inflammation; Updates Manufacturing Information On Reproxalap
Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated diseases, today announced at a…
-
11 months ago benzinga.com
BTIG Reiterates Buy on Aldeyra Therapeutics, Maintains $9 Price Target
BTIG analyst Thomas Shrader reiterates Aldeyra Therapeutics (NASDAQ:ALDX) with a Buy and maintains $9 price target.
1 year ago benzinga.com
4 Biotechnology Stocks Lead Momentum Gains Amid Strong Technicals
4 biotech stocks—ALDX, ALEC, BDTX, CHRS—show strong week-on-week momentum ranking gains and improving technical indicators.
1 year ago benzinga.com
4 Biotech Stocks Seeing Explosive Momentum Gains
The SPDR S&P Biotech ETF (ARCA:XBI) is up more than 40% over the past six months and is on the verge of breaking out. Here's a look at several momentum standouts in the biotech space that appear to…
-
1 year ago benzinga.com
Aldeyra Wins EMA Orphan Drug Status for ADX-2191 to Treat Rare Eye Cancer
Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) (Aldeyra) today announced that the European Medicines Agency (EMA) has granted Orphan Designation for ADX-2191 (methotrexate intravitreal injection, USP) for…
-
1 year ago benzinga.com
Aldeyra Therapeutics Says FDA Grants Fast Track Designation For ADX-2191 For Treatment Of Retinitis Pigmentosa
Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) (Aldeyra) today announced that the U.S. Food and Drug Administration (FDA) has granted fast track designation for ADX-2191 (methotrexate intravitreal…
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Friday's Intraday Session
12 Health Care Stocks Moving In Friday's Intraday Session